Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.

ISIS PHARMACEUTICALS, INC.

SELECTED FINANCIAL INFORMATION

Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Data)

Three months ended, Six months ended,

June 30, June 30,

2008 2007 2008 2007

Revenue: (unaudited) (unaudited)

Research and development revenue

under collaborative agreements $26,814 $3,482 $47,499 $5,484

Licensing and royalty revenue 6,147 331 6,815 779

Total revenue 32,961 3,813 54,314 6,263

Expenses:

Research and development 31,195 20,384 57,642 40,333

Selling, general and

administrative 4,899 3,089 8,635 6,491

Total operating expenses 36,094 23,473 66,277 46,824

Loss from operations (3,133) (19,660) (11,963) (40,561)

Other income (expense):

Investment income 560 3,053 5,515 6,454

Interest expense (1,391) (2,016) (2,788) (4,644)

Gain on investments, net - 1,989 - 3,510

Loss on early retirement of debt - (1,993) - (3,212)

Loss attributed to noncontrolling

interest in Symphony GenIsis, Inc. - 7,60
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... a bioMerieux company that develops innovative oncology diagnostic tests ... from a clinical study evaluating the company,s Breast Cancer ... the study were presented at the 33rd Annual CTRC-AACR ... The company also announced that the Breast Cancer Index ...
... 2010 Pfizer Inc. (NYSE: PFE ) ... it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment ... is approved (the European Union, Canada and Australia).  In ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) Pfizer,s decision ...
... (Dec. 9, 2010) -- Nanotechnologists, marine biologists and signal-processing ... Woods Hole, Mass., and other U.S. universities have won ... Research to unlock the secrets of nature,s best camouflage ... emulate some of the elegant skin colors and patterns ...
Cached Biology Technology:bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 2bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 3Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Nano squid skin: DOD awards $6M for metamaterials research 2Nano squid skin: DOD awards $6M for metamaterials research 3
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/10/2014)... , June 27, 2014  The American Academy ... Institute of Standards and Technology (NIST) and the ... academic research and forensic science expert members to ... is an element of the NIST,s Organization of ... among the first appointments made to the new ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... Ore. -- New research has found that if you want ... or other cruciferous vegetables, you need to eat the real ... absorbed and of far less value if taken as a ... Pauling Institute at Oregon State University, is one of the ...
... has awarded UC Santa Barbara up to $15 million ... shape the future of technology in areas that will ... educate future scientists and engineers and advance the discovery ... novel polymers to next-generation microelectronics. The pioneering institute ...
... them, and although they could be effective in theory, antivirulence ... to be published in the online journal mBio ... to fight infection while avoiding the pitfalls of drug resistance. ... growth of pathogens, but antivirulence drugs prevent disease by ...
Cached Biology News:Health benefits of broccoli require the whole food, not supplements 2Health benefits of broccoli require the whole food, not supplements 3UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education 2UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education 3Can antivirulence drugs stop infections without causing resistance? 2
Request Info...
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... high activity in primer extension and other ... of the enzyme, each lot has been ...
... Gold® DNA Polymerase is a chemically modified ... chemical moiety is attached to the enzyme, ... the first ramp of thermal cycling (when ... temperatures), the enzyme is inactive. The result ...
Biology Products: